UCART22

· Cellectis S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UCART22, covering 2025-09-09 to 2025-09-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) [Phase 1, Phase 2]

See pricing